Randomization will be into a Control Arm, and MCD 1 Arm, and an MCD 2 arm. Participants in all arms are offered standard of care cancers screenings.
The Control Arm has no additional tests. The MCD 1 Arm will receive the multi-cancer detection test labelled 1, which can detect cancers, A, B, and C. The MCD 2 Arm will receive the multi-cancer detection test labeled 2, which can detect cancers C, D, and E.
The objectives of the vanguard study are to:
- assess participant willingness for randomization;
- determine adherence to testing and diagnostic follow-up;
- evaluate feasibility of protocol-defined diagnostic workflows;
- determine reliability and timeliness of blood specimen testing and return by MCD companies; and
- identify facilitators and barriers to recruitment/retention/compliance of diverse participant groups.